



Interim Results
Six months ended 30 September 2014



Disclaimer

The information in this document and the related presentation do not constitute or form any part of, and should not be construed as, an offer or invitation to sell, or issue, or any solicitation of any offer to purchase, subscribe for or otherwise acquire any share or other securities in Omega Diagnostics Group PLC ("Omega") in any jurisdiction, nor shall it or any part of it form the basis of, or be relied on in connection with, any contract therefore. No reliance may be placed for any purpose whatsoever on the information or opinions contained in this document and the presentation or their completeness. No representation or warranty, expressed or implied, is given on behalf of Omega or any of its respective directors, employees, agents or advisers as to the accuracy, completeness or fairness of the information or opinions contained herein or made in the presentation and, save in the case of fraud, no responsibility or liability is accepted (and all such liability is hereby excluded) for any such information or opinions.

Readers of this document and recipients of the presentation are reminded that any decision to acquire shares in Omega should be made only on the basis of information contained in the final admission document to be issued by Omega which may be different from the information contained in this document. The information in this document may not be reproduced or further distributed to any other person or published, in whole or in part, for any purpose. Neither this document (or any copy of it) nor the information in the presentation may be sent or taken into the United States, Canada, Australia or Japan, nor may it be distributed to any US person (within the meaning of regulation S under the US Securities Act of 1933, as amended).

Furthermore, this document and presentation are strictly only for persons who are investment professionals within the meaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2001 (SI 2001/1335), as amended, (the "FPO") or persons falling within paragraph 49 of the FPO (high net worth companies, unincorporated associations etc.) or to persons to whom it may otherwise be lawful for these materials to be communicated ("Permitted Recipients"). Any persons who are not Permitted Recipients should not stay for the remainder of this presentation and, in any event, must not act or rely upon the information contained in this presentation and document. By staying for the remainder of this presentation and/or receiving this document, each participant is deemed to confirm that they are a Permitted Recipient.

The Omega Presentation Team

- “ Andrew Shepherd – Chief Executive
- “ Kieron Harbinson – Finance Director
- “ Jag Grewal – Sales & Marketing Director
- “ Dr Edward Valente – R&D Director


Agenda

- “ Financial results
- “ Allersys update
- “ Visitect® CD4 technical update
- “ Visitect® CD4 market update
- “ Q & A


Financial KPIs

Six months ending 30 September 2014


Sales (£m)
£5.7m ▲ 2%




Gross profit (£m)
£3.7m ▲ 3%




Gross profit (%)
64% ▲ 1%




Adjusted PBT (£m)
£0.56m ▲ 32%



Tax (charge)/credit £k
(£29k)



Adjusted EPS
0.5p ▼ 8%



Adjusted PBT stated before acquisition costs, share-based payments, IFRS-related discount unwinds and amortisation of intangible assets

Cash Flow

Eighteen months ending 30 September 2014

	18 months ended 30-Sep-14	Exclude non-recurring items	18 month recurring cash burn
Operating profit	0.7	-	0.7
W/cap movements	1.3	(0.3)	1.0
Operating cash flow	2.0	(0.3)	1.7
Capex	(0.9)	-	(0.9)
Capitalised R&D/Licences	(2.5)	0.5	(2.0)
New share issue	3.7	(3.7)	-
Loan repayments	(0.7)	0.7	-
Finance leases	0.5	-	0.5
Cash at end of period	2.1	(2.8)	(0.7)

Core Business Update

Headwinds

- “ Currency effect of a stronger pound.
- “ Continued reimbursement pressure in Germany leading to reduction in sales in some regions.
- “ Delayed order fulfilment due to raw material supply in our Infectious Disease segment.




Flagship Product Sales

Six months ending 30 September 2014

Genarrayt Reagent Sales

Top five markets = 70% of sales


EU and North America driving growth



Food Detective Sales

Top five markets = 66% of sales

EU and BRIC driving growth





Allersys Development Programme Update



Allersys Development Programme

Current status

- “ 27 allergens optimised (target launch 40 allergens).
- “ 22 allergens have completed claim support.
- “ Manufacturing equipment installed and validated.
- “ Transfer of optimisation in-house.
- “ Three new scientists recruited in Scotland to undertake optimisation experiments.
- “ Commercialisation discussions continue with IDS and partners in key launch countries.



Allersys Development Programme

Optimisation

- Create assay and ensure equivalent performance to predicate device.
- 13 allergens.


Claim Support

- Verification phase – Ensures design goals are met.
- 5 allergens

CE Mark & Transfer

- Final transfer to manufacturing.
- Beta site (customer lab) studies Q1 calendar 2015
- 22 allergens

Visitect® CD4 Technical Update



Visitect® CD4 summary to date

- Technical transfer from Burnet directly to contracted manufacturer, managed by Omega
- 3 batches successfully manufactured – Feb 2014

- Devices sent to Indian site-pilot study
- Interim analysis of Indian site results allows same batch of devices to be sent to Kenya for NGO run study

- India results good, bias observed between finger prick and venous blood
- Kenya results sub-optimal compared to India. So far root cause not established.

Visitect® CD4 summary to date


The Key Issue- batches made subsequent to the 3 batches are variable

For now Kenya and finger-prick vs venous blood are of secondary concern


There are variables which require further investigation.

Visitect® CD4

Device architecture




Visitect[®] CD4 Forward plan



1. Set up bench top processes exactly as Burnet used
2. Establish major source of variability
3. Improve sample testing turn-around time to expedite investigations
4. Deliberately make devices fail to ensure we definitely identify which levers are important
5. Engagement with experts in lateral flow technology
6. Co-inventor and lead development scientist from Burnet will revisit to work with Omega team
7. Decide on suitable processes for manufacture
8. Manufacture batches
9. Re-commence external studies- in particular we have agreement with Kenya to allow Omega to be present during a “run-in” phase.

Visitect® CD4 Market Update



HIV a major public health issue

Adults and children estimated to be living with HIV | 2013



Total: 35.0 million [33.2 million . 37.2 million]




Total: 18.0 million people in need of treatment are not receiving it



CD4 Market Potential Confirmed

CD4/Viral Load/ EID: Projected Procurement 2012-2013

Total: USD 91.2 million for 300 procurement plans



Source: Procurement plans for approved grants

GF Diagnostic QA
AMDS MAY 2013



Summary

Core business remains profitable and cash generative

27 allergens optimised on the iSYS instrument

Increased technical input and support into CD4 project

Significant CD4 market accessible via Global Health partners

High demand for POC CD4 tests

APPENDICES

Omega Diagnostics Group PLC

A brief history

1987

Omega Diagnostics Ltd founded



2006

Omega Diagnostics Group PLC Public Listing

G·E·N·E·S·I·S
Diagnostics



2007

Acquisition of Genesis Diagnostics and Cambridge Nutritional Sciences

2009
Acquisition of Co-Tek

2010

Acquisition of IVD Division of Allergopharma




2011

Formation of Indian Subsidiary Omega Dx (Asia) Pvt Ltd.



Core Markets




A global reach allows the group to benefit from fast growing economies in emerging markets while simultaneously mitigating challenging economic and political instability in certain regions of the world.

- Countries where our products are distributed
- Countries where we have a direct presence

Group Turnover – year ended 31 March 2014

Revenue share


£4.0m



Allergy and
autoimmune

Revenue share


£5.2m



Food intolerance

Revenue share

£2.4m



Infectious disease

Omega Management Team

